ArticleFrontiers in oncology2025
Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between autoantibody profiles and immune checkpoint inhibitor (ICI) therapy in cancer patients remains incompletely characterized. This cross-sectional study investigated serum autoantibody (AAb) prevalence and profiles across multiple tumor types before and after ICI therapy. Methods: This study analyzed serum autoantibodies in 808 participants: 358 treatment-naïve cancer patients (ICI- group), 250 cancer patients following ≥6 months of ICI therapy (ICI+ group), and 200 healthy controls (HC). The cancer cohort comprised 10 solid tumor types. Serum samples were analyzed for antinuclear antibodies (ANA), antiphospholipid antibodies (aPL), anti-neutrophil cytoplasmic antibodies (ANCA), and anti-thyroid antibodies (ATA) using automated quantitative immunoassays. Results: Cancer patients demonstrated significantly elevated AAb prevalence compared to healthy controls. The ICI- group showed positivity rates of 20.1% for ANA, 11.5% for aPL, 1.7% for ANCA, and 17.3% for ATA, compared to 10.5%, 4.5%, 1.5%, and 9.5% in healthy controls, respectively. After ICI therapy, ANA positivity increased to 33.6%. CTLA-4 inhibitor recipients demonstrated higher ANA frequencies than PD-1/PD-L1 monotherapy recipients (57.1% vs 27.1%),. Tumor stage did not significantly influence AAb prevalence. Colorectal, hepatocellular, and renal cancers showed significant ANA increases after ICI treatment. Anti-Scl-70, anti-SSA-60, and anti-RNP were the most frequently elevated ANA subtypes. Anti-thyroglobulin was the most responsive ATA subtype following ICI therapy. Conclusions: ANA profiles vary across tumor types and differ between treatment-naïve and ICI-treated patients. CTLA-4-treated patients exhibit higher ANA frequency. Different tumors exhibit distinct preferences for AAb expression patterns. Serum AAb profiling may serve as a valuable tool for immunotherapy monitoring and risk stratification for immune-related adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.